Allergic Asthma Due to Dermatophagoides Farinae, Allergic Asthma Due to Dermatophagoides Pteronyssinus, Allergic Rhinitis Due to House Dust Mite
Conditions
Keywords
Allergy, Allergic Rhinitis, Allergic Asthma, House Dust Mite, Immunotherapy
Brief summary
Non-interventional study to investigate the safety and tolerability of allergy immunotherapy ACARIZAX® 12 SQ-HDM in real-life clinical practice in adults patients (\>18 years) with house dust mite allergy over a period of 12 months.
Detailed description
Condition: * persistent moderate to severe HDM allergic rhinitis despite use of symptom-relieving medication * HDM allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe HDM allergic rhinitis. Patients' asthma status should be carefully evaluated before the initiation of treatment.
Interventions
DRUGTablet, Dispersible
1 tablet/day with 12 SQ-HDM per lyo-tablet
Sponsors
ITEC Services
ALK-Abelló A/S
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* At the discretion of the investigator, patient who will be prescribed ACARIZAX® in line with the approved Summary of Product Characteristics (SmPC) and who have been informed, after explicit written explanation and willing to participate in the study by signed consent
Exclusion criteria
* Patient who did not have 12 months prior inclusion or have an on-going, House Dust Mite (HDM) Allergy Immunotherapy (AIT).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety analysis: Number of patients with at least one Adverse Event | 1 year | Number of patients with at least one Adverse Events related to ACARIZAX®. |
Countries
France
Outcome results
None listed